- Home
- KRG vs LEGN Comparison
KRG vs LEGN Comparison
Compare KRG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRG | LEGN |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KRG | LEGN |
|---|---|---|
| Price | $27.61 | $19.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $26.00 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 2.4M | 2.3M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | ★ 6750.00 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $844,365,000.00 | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | $0.96 | $30.52 |
| P/E Ratio | $33.35 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $20.86 | $16.24 |
| 52 Week High | $29.92 | $38.42 |
Technical Indicators
Market Signals| Indicator | KRG | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | N/A |
| Support Level | $26.68 | N/A |
| Resistance Level | $29.55 | N/A |
| Average True Range (ATR) | 0.59 | 0.00 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 0.96 | 0.00 |
Price Performance
Historical ComparisonAbout KRG Kite Realty Group Trust
Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.